Valneva Q1 Earnings Call Highlights
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
Valneva Announces the Successful Completion of an €84 million Reserved Offering
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
Declaration of shares and voting rights of Valneva SE – March 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
Head-To-Head Contrast: Medtronic (NYSE:MDT) versus Valneva (NASDAQ:VALN)
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
Financial Survey: Valneva (NASDAQ:VALN) and Sharps Technology (NASDAQ:STSS)
VALNEVA Declaration of shares and voting rights: February 28, 2026
Valneva to Participate in Upcoming Investor Conferences
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
VALNEVA Declaration of shares and voting rights: January 31, 2026
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?
Valneva withdraws application for standard US approval of its chikungunya shot
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Valneva rencontrera des investisseurs lors de la J.P. Morgan Healthcare Conference
Valneva SE - Declaration of voting rights - December 2025
Valneva (NASDAQ:VALN) Trading Up 4.9% – Still a Buy?
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
VALNEVA Declaration of shares and voting rights: November 30, 2025
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva to Further Consolidate its Operations in France